|
Haemonetics Corporation (HAE) DCF Valuation |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
Haemonetics Corporation (HAE) Bundle
Enhance your investment choices with the Haemonetics Corporation (HAE) DCF Calculator! Utilize actual financial data from Haemonetics, adjust growth projections and expenses, and instantly observe how these alterations affect the intrinsic value of Haemonetics Corporation (HAE).
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2021 |
AY2 2022 |
AY3 2023 |
AY4 2024 |
AY5 2025 |
FY1 2026 |
FY2 2027 |
FY3 2028 |
FY4 2029 |
FY5 2030 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 870,5 | 993,2 | 1 168,7 | 1 309,1 | 1 360,8 | 1 523,2 | 1 705,0 | 1 908,5 | 2 136,2 | 2 391,1 |
| Revenue Growth, % | 0 | 14.1 | 17.67 | 12.01 | 3.95 | 11.93 | 11.93 | 11.93 | 11.93 | 11.93 |
| EBITDA | 142,3 | 178,5 | 249,3 | 265,6 | 221,8 | 281,0 | 314,5 | 352,1 | 394,1 | 441,1 |
| EBITDA, % | 16.34 | 17.97 | 21.34 | 20.29 | 16.3 | 18.45 | 18.45 | 18.45 | 18.45 | 18.45 |
| Depreciation | 84,3 | 97,7 | 93,3 | 97,2 | ,0 | 106,4 | 119,1 | 133,3 | 149,3 | 167,1 |
| Depreciation, % | 9.68 | 9.84 | 7.98 | 7.43 | 0 | 6.99 | 6.99 | 6.99 | 6.99 | 6.99 |
| EBIT | 58,0 | 80,8 | 156,0 | 168,4 | 221,8 | 174,6 | 195,4 | 218,7 | 244,8 | 274,0 |
| EBIT, % | 6.66 | 8.13 | 13.35 | 12.86 | 16.3 | 11.46 | 11.46 | 11.46 | 11.46 | 11.46 |
| Total Cash | 192,3 | 259,5 | 284,5 | 178,8 | 306,8 | 331,3 | 370,9 | 415,1 | 464,7 | 520,1 |
| Total Cash, percent | 22.09 | 26.13 | 24.34 | 13.66 | 22.54 | 21.75 | 21.75 | 21.75 | 21.75 | 21.75 |
| Account Receivables | 127,6 | 159,4 | 179,1 | 206,6 | 202,7 | 233,7 | 261,5 | 292,8 | 327,7 | 366,8 |
| Account Receivables, % | 14.65 | 16.05 | 15.33 | 15.78 | 14.89 | 15.34 | 15.34 | 15.34 | 15.34 | 15.34 |
| Inventories | 322,6 | 293,0 | 259,4 | 317,2 | 365,1 | 426,0 | 476,8 | 533,7 | 597,4 | 668,7 |
| Inventories, % | 37.06 | 29.5 | 22.19 | 24.23 | 26.83 | 27.96 | 27.96 | 27.96 | 27.96 | 27.96 |
| Accounts Payable | 50,3 | 58,4 | 63,9 | 73,4 | 67,0 | 84,2 | 94,3 | 105,5 | 118,1 | 132,2 |
| Accounts Payable, % | 5.78 | 5.88 | 5.47 | 5.6 | 4.92 | 5.53 | 5.53 | 5.53 | 5.53 | 5.53 |
| Capital Expenditure | -37,0 | -96,5 | -110,2 | -66,3 | -39,3 | -95,5 | -106,9 | -119,7 | -133,9 | -149,9 |
| Capital Expenditure, % | -4.26 | -9.72 | -9.43 | -5.06 | -2.89 | -6.27 | -6.27 | -6.27 | -6.27 | -6.27 |
| Tax Rate, % | 20.93 | 20.93 | 20.93 | 20.93 | 20.93 | 20.93 | 20.93 | 20.93 | 20.93 | 20.93 |
| EBITAT | 63,2 | 55,0 | 127,3 | 130,3 | 175,4 | 141,8 | 158,8 | 177,7 | 198,9 | 222,7 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -289,5 | 62,1 | 129,9 | 85,4 | 85,7 | 78,2 | 102,3 | 114,5 | 128,2 | 143,5 |
| WACC, % | 5.43 | 5.34 | 5.38 | 5.37 | 5.37 | 5.38 | 5.38 | 5.38 | 5.38 | 5.38 |
| PV UFCF | ||||||||||
| SUM PV UFCF | ,0 | ,0 | ,0 | ,0 | ,0 | ,0 | ,0 | ,0 | ,0 | 478,6 |
| Long Term Growth Rate, % | 4.00 | |||||||||
| Free cash flow (T + 1) | 149 | |||||||||
| Terminal Value | 10,826 | |||||||||
| Present Terminal Value | 8,331 | |||||||||
| Enterprise Value | 8,810 | |||||||||
| Net Debt | -3 | |||||||||
| Equity Value | 8,813 | |||||||||
| Diluted Shares Outstanding, MM | 51 | |||||||||
| Equity Value Per Share | 173.73 |
What You Will Get
- Editable Forecast Inputs: Easily modify assumptions (growth %, margins, WACC) to generate various scenarios.
- Real-World Data: Haemonetics Corporation’s financial data pre-filled to kickstart your analysis.
- Automatic DCF Outputs: The template computes Net Present Value (NPV) and intrinsic value for you.
- Customizable and Professional: A refined Excel model that adapts to your valuation requirements.
- Built for Analysts and Investors: Perfect for testing projections, validating strategies, and saving time.
Key Features
- 🔍 Real-Life HAE Financials: Pre-filled historical and projected data for Haemonetics Corporation.
- ✏️ Fully Customizable Inputs: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates.
- 📊 Professional DCF Valuation: Built-in formulas calculate Haemonetics’ intrinsic value using the Discounted Cash Flow method.
- ⚡ Instant Results: Visualize Haemonetics’ valuation instantly after making changes.
- Scenario Analysis: Test and compare outcomes for various financial assumptions side-by-side.
How It Works
- 1. Access the Template: Download the Excel file containing Haemonetics Corporation’s (HAE) preloaded financial data.
- 2. Modify Assumptions: Adjust key parameters such as growth rates, WACC, and capital expenditures.
- 3. Analyze Results Instantly: The DCF model automatically computes intrinsic value and NPV in real-time.
- 4. Explore Scenarios: Evaluate various forecasts to assess different valuation results.
- 5. Present with Assurance: Deliver expert valuation insights to enhance your decision-making process.
Why Choose This Calculator for Haemonetics Corporation (HAE)?
- Accuracy: Utilizes real Haemonetics financial data for precise calculations.
- Flexibility: Allows users to easily test and adjust inputs as needed.
- Time-Saving: Eliminate the need to construct a DCF model from the ground up.
- Professional-Grade: Crafted with the expertise and usability expected at the CFO level.
- User-Friendly: Intuitive interface suitable for users with varying levels of financial modeling experience.
Who Should Use Haemonetics Corporation (HAE)?
- Healthcare Investors: Make informed investment choices with a comprehensive analysis of Haemonetics' market position.
- Medical Financial Analysts: Utilize a streamlined valuation model tailored for healthcare sector analysis.
- Consultants: Efficiently modify the framework for client reports or presentations related to Haemonetics.
- Healthcare Enthusiasts: Enhance your knowledge of the medical device industry through real-life case studies.
- Educators and Students: Apply it as a practical resource in healthcare finance and investment courses.
What the Template Contains
- Pre-Filled DCF Model: Haemonetics Corporation’s financial data preloaded for immediate use.
- WACC Calculator: Detailed calculations for Weighted Average Cost of Capital.
- Financial Ratios: Evaluate Haemonetics Corporation’s profitability, leverage, and efficiency.
- Editable Inputs: Change assumptions such as growth, margins, and CAPEX to fit your scenarios.
- Financial Statements: Annual and quarterly reports to support detailed analysis.
- Interactive Dashboard: Easily visualize key valuation metrics and results.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.